WT1 protein-derived peptide vaccine DSP-7888

Drug Overview

The medication known as WT1 protein-derived peptide vaccine DSP-7888 is a cutting-edge cancer vaccine designed to train the body’s own immune system to fight cancer. It is not a traditional medicine like chemotherapy that kills cells directly. Instead, it is a “Smart Drug” classified as a therapeutic peptide vaccine. It works by “teaching” the immune system to recognize a specific protein that is often found in large amounts on cancer cells but is rare in healthy cells.

Here are the key details about this agent:

• Generic Name: WT1 protein-derived peptide vaccine DSP-7888 (also known as ademuzotide).
• US Brand Names: None yet. It is currently an investigational drug used in clinical trials.
• Drug Class: Cancer Vaccine / Immunotherapy / Peptide-based Antigen.
• Route of Administration: Subcutaneous (under the skin) or Intradermal (into the skin) injection.
• FDA Approval Status: Currently investigational. It is not yet FDA-approved for standard public use, but it has been granted “Orphan Drug” status for certain brain cancers.

What Is It and How Does It Work? (Mechanism of Action)

To understand how DSP-7888 works, imagine your immune system is a security team. Sometimes, cancer cells act like “stealth” invaders that the security team cannot see. DSP-7888 acts like a “wanted poster” that shows the security team exactly what the enemy looks like.

The Targeted Protein: WT1

The “WT1” in the name stands for Wilms’ Tumor protein 1. This protein is like a fingerprint for many types of cancer. Most healthy adult cells do not have much of this protein, but many cancer cells produce it in massive amounts to help the tumor grow.

Molecular Level Function

1. Instruction: DSP-7888 contains two small fragments of the WT1 protein (peptides). These fragments are specifically designed to be recognized by the body’s immune soldiers, known as T-lymphocytes.
2. Recognition: After the vaccine is injected, specialized “scout cells” (Dendritic Cells) pick up these peptides. They present the peptides to the immune system’s “killer” cells (CD8 cytotoxic T-cells) and “helper” cells (CD4 T-cells).
3. Activation: Once these T-cells “see” the WT1 fragments, they become activated and multiply. They are now programmed to hunt for anything in the body that carries the WT1 fingerprint.
4. The Attack: These newly trained T-cells travel through the blood. When they find a cancer cell expressing the WT1 protein, they lock onto it and release toxic chemicals that destroy the cancer cell while leaving healthy cells alone.

By using both “killer” and “helper” peptides, DSP-7888 aims to create a stronger and longer-lasting immune memory against the cancer.

FDA-Approved Clinical Indications

Because DSP-7888 is an investigational agent, it does not currently have official FDA-approved indications for routine clinical practice. However, it is being extensively studied in approved clinical trials for the following purposes:

Oncological Uses (In Clinical Trials):

• Glioblastoma (GBM): A serious type of brain cancer. It is being studied to see if it can prevent the tumor from growing back after surgery and radiation.
• Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS): Blood cancers where the WT1 protein is highly active.
• Pediatric High-Grade Gliomas: Brain tumors in children.
• Solid Tumors: Including some types of lung and ovarian cancers that show high WT1 levels.

Non-oncological Uses:

• There are currently no non-cancer uses for DSP-7888.

Dosage and Administration Protocols

DSP-7888 is administered as an injection, usually by a nurse or doctor in a clinic. Unlike chemotherapy, which can take hours, this injection is very quick.

Clinical Efficacy and Research Results

Recent clinical studies (conducted between 2020 and 2025) have looked closely at how DSP-7888 helps patients with brain and blood cancers.

• Immune Response: In Phase 1 and 2 trials, researchers found that a high percentage of patients (often over 70 percent) showed an increase in WT1-specific T-cells in their blood after treatment.
• Glioblastoma Results: In some studies of patients with recurrent glioblastoma, the vaccine was combined with other drugs (like bevacizumab). While it did not work for everyone, a subset of patients saw their disease stay stable for several months longer than expected.
• Safety and Survival: Data from 2024 studies suggest that the vaccine is very well tolerated. In blood cancer trials, patients who had a strong immune reaction to the vaccine tended to have better “Overall Survival” rates compared to those who did not respond to the vaccine.

Safety Profile and Side Effects

Because DSP-7888 is an immunotherapy, its side effects are very different from traditional chemotherapy. Most side effects are signs that the immune system is “waking up.”

Common Side Effects (greater than 10 percent):

• Injection Site Reactions: Redness, swelling, itching, or a small hard bump where the needle went in.
• Fatigue: Feeling tired or wiped out for a few days after the shot.
• Flu-like Symptoms: Low-grade fever, chills, or muscle aches.
• Headache: Mild to moderate head pain.

Serious Adverse Events:

• Severe Allergic Reactions (Rare): As with any vaccine, a very small number of people may have a serious allergic reaction (anaphylaxis).
• Immune-Related Inflammation: In rare cases, the immune system might get too excited and cause inflammation in healthy organs, though this is less common with peptide vaccines than with other immunotherapies.

Black Box Warning: There is no FDA Black Box Warning for this investigational agent.

Management Strategies:

• For Injection Site Pain: A cold compress can be applied to the area.
• For Flu-like Symptoms: Over-the-counter pain relievers like acetaminophen are often recommended.
• Monitoring: Patients are usually asked to wait in the clinic for 30 minutes after the injection to ensure they do not have an allergic reaction.

Connection to Stem Cell and Regenerative Medicine

DSP-7888 has a strong connection to Stem Cell Research and Immunotherapy. In blood cancers, patients often receive a “Hematopoietic Stem Cell Transplant” to rebuild their blood system. However, there is always a risk that a few cancer cells might hide and grow back.

Researchers are studying if giving DSP-7888 after a stem cell transplant can help the “new” immune system find and kill those hidden cancer cells. By using the vaccine to “train” the new immune cells produced by the transplanted stem cells, doctors hope to create a permanent shield against the return of the leukemia. This is a form of regenerative immunotherapy, where the body’s self-repair system is taught to be a long-term cancer guardian.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed:

• HLA Typing: A blood test to see if your immune system type is compatible with the vaccine.
• WT1 Expression Test: A biopsy or blood test to confirm your cancer actually has the WT1 protein.
• Baseline Blood Counts: To check your starting levels of white blood cells.

Precautions During Treatment:

• Steroid Use: Tell your doctor if you are taking steroids (like dexamethasone). High doses of steroids can “quiet” the immune system and might make the vaccine less effective.
• Immune Status: If you develop a high fever or infection, your doctor may delay your injection until you are better.

“Do’s and Don’ts” List:

• DO stay hydrated and rest on the day of your injection.
• DO keep the injection site clean and dry for 24 hours.
• DON’T ignore any sudden difficulty breathing or swelling of the face after an injection.
• DON’T apply medicated creams or ointments to the injection site unless told by your medical team.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. DSP-7888 is an investigational agent and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and eligibility for clinical trials.